Compounds > 1,2-distearoyllecithin
Page last updated: 2024-08-24

1,2-distearoyllecithin and Breast Neoplasms

1,2-distearoyllecithin has been researched along with Breast Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Douroumis, D; Nandi, U; Onyesom, I1
Benazzouz, F; Cordobes, MD; de Beco, V; Moretti, JL; Starzec, A1

Other Studies

2 other study(ies) available for 1,2-distearoyllecithin and Breast Neoplasms

ArticleYear
An in vitro evaluation of antitumor activity of sirolimus-encapsulated liposomes in breast cancer cells.
    The Journal of pharmacy and pharmacology, 2021, Mar-06, Volume: 73, Issue:3

    Topics: 1,2-Dipalmitoylphosphatidylcholine; 3T3 Cells; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Humans; Liposomes; Mice; Nanoparticles; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Sirolimus; Time Factors

2021
Uptake of liposome-encapsulated 99Tcm-MIBI by sensitive and multidrug-resistant tumour cell lines.
    Nuclear medicine communications, 1999, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Biological Transport; Breast Neoplasms; Carcinoma, Small Cell; Cholesterol; Drug Resistance, Multiple; Female; Humans; Kinetics; Liposomes; Lung Neoplasms; Mouth Neoplasms; Phosphatidylcholines; Phosphatidylethanolamines; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tumor Cells, Cultured

1999